+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Competent Cells Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • ID: 4987014
  • Report
  • February 2021
  • Region: Global
  • 110 pages
  • Mordor Intelligence

FEATURED COMPANIES

  • Avantor
  • Genscript Corporation
  • HiMedia Laboratories
  • Lucigen Corporation
  • Merck KGaA
  • Scarab Genomics
The competent cells market was estimated to be USD 1,625 million in 2020 and is expected to reach USD 2,790 by the year 2026, growing at a CAGR of 9.4% over the forecast period.

The COVID-19 pandemic is having a significant effect on the competent cell market. Research and development activities have increased in the biotechnology field as a result of the pandemic. Cell cloning activities like recombinant protein expression and mutagenesis have seen increased focus since the COVID-19 pandemic due to which the market is seeing robust growth. To better study the SARS-nCoV genome, there has been a huge demand for competent cells for making cloned copies of viral plasmids. For example, in May 2020, a paper was published in 'Cell Host & Microbe' which reported the construction of a full-length SARS-CoV-2 genome via in-vitro competent cells.

Advancements in molecular engineering due to the emergence of new cell technologies in biotechnology industries are augmenting the growth of the market studied. Additionally, increased investments from public and private companies and the introduction of novel product types are anticipated to boost the market growth in the studied regions. For example, Thermo Fisher, an American company, manufactures the ElectroMAX Stbl4 line of competent cells which can be used for high-efficiency cloning of unstable DNA, including repetitive DNA and retroviral sequences when genomic and cDNA library construction is done. It manufactures other products like MultiShot StripWell Mach1 T1 Phage-Resistant cells and ElectroMAX DH10B T1 Phage-Resistant cells which are both used for cloning purposes.

In Germany, private biotechnology firms attracted around EUR 369 million in venture capital investment in 2018, according to BIO Deutschland. Public biotechnology firms were also able to raise some EUR 693 million from the stock market in 2018. Such high amounts of capital raising capabilities from major companies is likely to lead to further investment in research and development activities. This is expected to have a positive effect on market development.

However, the very high cost of research and development of competent cells coupled with market consolidation of a few major players are expected to hamper the market growth over the period.

Key Market Trends

Cloning Application Expected to Register Good Growth Rate Over the Forecast Period

Cloning, in the application segment, is projected to grow at significant rates owing to the high demand for molecular cloned products. COVID-19 has had a positive impact on the cloning industry as it has ushered in increased research and development investments by companies. Furthermore, the increase in research on cloning and financial support from various agencies is expected to boost the segment growth. Cell engineering techniques like somatic cell nuclear transfer (SCNT) have been shown to have a wide range of applications in generating transgenic animals, protecting endangered animals, and therapeutic cloning. These areas are likely to see renewed interest due to which demand for competent cells will increase as they can be used in therapeutic cloning research.

The biotechnology segment is also projected to witness a notable growth rate due to rising investments in R&D and commercialization of proteomics and genomic-based products. Furthermore, the need for advanced product technologies in the treatment of various diseases is projected to bolster segment growth.

In addition, increased funding on studies for DNA cloning technologies in academic research institutions and use of these products in therapeutics is anticipated to strengthen the market growth in the near future.

Asia-Pacific is Expected to Show Good Growth Over the Forecast Period

The Asia-Pacific market is anticipated to have a majority of the share globally. The growth is attributed to extensive studies on DNA cloning technologies in the regions and the presence of key market players. For example, in January 2021, Takara Bio Inc. announced the completion of its new facility called the Center for Gene and Cell Processing II for research and manufacturing purposes in Shiga, Japan.

Furthermore, continuous support from governments in advancing DNA technologies and growing demand for cloned products expected to boost the market growth over the forecast period. For example, the Chinese Government has played a significant role in the development of biotechnology industries in the country. In June 2019, the China Bio-Industry Conference was held and was jointly sponsored by the Chinese Society of Bioengineering and the Guangdong Provincial Government. At the conference, the Guangzhou Nanshan Science and Technology Innovation Fund was launched as a public-private partnership with some 200 million RMB in financing for biotech companies willing to do their research in the region. Initiatives such as these are expected to have a positive impact on the development of genetic engineering industries which will further create demand for competent cells. In addition, combining the artificial intelligence in developing the products and growing research & development on DNA technologies in research institutions are projected to bolster the market growth. Moreover, the need for advanced products for the treatment of diseases and favourable regulatory policies are supplementing the market growth.

Another company from the region, India based HiMedia Solutions manufactures many products for the competent cells market. It's four major products for the studied market includes Bacterial Transformation kit, HiPurA BL21(DE3) Competent Cells, HiPurA Competent Cells and HiPurA XL1-Blue Competent Cells. The company is the premier manufacturer of competent cells in India. Some of its products, like the HiPurA Competent Cells was the first chemically competent DH5a cells offered in the Indian market which makes cloning experiments easier. Presence of such companies are likely to have a positive effect on market development.

Moreover, the advent of innovative technologies in countries like South Korea, Japan and Singapore, and the need for commercial cloning products for therapeutic uses is predicted to aid the market share over the forecast period. The Asia-Pacific region is anticipated to have a significant growth rate owing to the developing healthcare and research infrastructure especially in emerging countries of the region.

Competitive Landscape

The competent cells market is moderately consolidated having a notable number of market players. Companies are focusing on developing new technologies in cell DNA cloning and broadening the applications of competent cells. The key market players operating in the market include Thermo Fisher Scientific, Merck KGaA, Qiagen, Takara Bio Inc., and New England BioLabs Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Avantor
  • Genscript Corporation
  • HiMedia Laboratories
  • Lucigen Corporation
  • Merck KGaA
  • Scarab Genomics
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Commercial Demand and Continuous Support From Government and Educational Institutions
4.2.2 Advancements in Cell Technologies in Healthcare
4.3 Market Restraints
4.3.1 High Cost of Research and Development
4.3.2 Growing Market Consolidation and Difficult Market Entry
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Chemically Competent
5.1.2 Electrocompetent
5.2 By Application
5.2.1 Protein Expression
5.2.2 Cloning
5.2.3 Biotechnology
5.2.4 Others
5.3 By End-User
5.3.1 Biopharmaceutical Companies
5.3.2 Contract Research Organizations
5.3.3 Academic Institutions
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific
6.1.2 Merck KGaA
6.1.3 Agilent Technologies, Inc.
6.1.4 Takara Bio Inc.
6.1.5 New England Biolabs (UK) Ltd.
6.1.6 HiMedia Laboratories
6.1.7 Zymo Research
6.1.8 Avantor
6.1.9 TransGen Biotech Co., Ltd
6.1.10 Scarab Genomics
6.1.11 Lucigen Corporation
6.1.12 Genscript Corporation
6.1.13 Tonbo Biosciences
6.1.14 Enzynomics co Ltd
6.1.15 Klee GmbH
6.1.16 NZYTech, Lda

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
  • Thermo Fisher Scientific
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Takara Bio Inc.
  • New England Biolabs (UK) Ltd.
  • HiMedia Laboratories
  • Zymo Research
  • Avantor
  • TransGen Biotech Co., Ltd
  • Scarab Genomics
  • Lucigen Corporation
  • Genscript Corporation
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll